Sugi Predict

Sugi Predict / Compounds / SCHEMBL3410685

SCHEMBL3410685

SCHEMBL3410685

C[C@]12C(O)=CC(=O)C=C1CC[C@@H]1[C@@H]2C(O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HIF1A Q16665 11/20 0.72
▸ HSD17B10 Q99714 10/20 0.72
▸ NR3C1 P04150 6/20 0.72
▸ PGR P06401 6/20 0.72
▸ CYP3A4 P08684 5/20 0.72
▸ CYP2C19 P33261 4/20 0.72
▸ SERPINA6 P08185 4/20 0.72
▸ NR3C2 P08235 2/20 0.72
▸ ABCB11 O95342 2/20 0.72
▸ AR P10275 2/20 0.72
▸ TNF P01375 1/20 0.72
▸ IL6 P05231 1/20 0.72
▸ GLUL P15104 1/20 0.72
▸ ADAM17 P78536 1/20 0.72
▸ GPBAR1 Q8TDU6 1/20 0.72
▸ KMT2A Q03164 3/20 0.67
▸ SHBG P04278 2/20 0.67
▸ SMN1; SMN2 Q16637 2/20 0.67
▸ MAPT P10636 1/20 0.67
▸ NFKB1 P19838 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1182565 1.00 HIF1A (0.72) HIF1AHSD17B10NR3C1PGRCYP3A4
SCHEMBL1512721 0.90 HIF1A (0.72) HIF1AHSD17B10NR3C1PGRCYP3A4
SCHEMBL2299293 0.90 HIF1A (0.72) HIF1AHSD17B10NR3C1PGRCYP3A4
SCHEMBL13270299 0.90 HIF1A (0.72) HIF1AHSD17B10NR3C1PGRCYP3A4
SCHEMBL11484589 0.90 HIF1A (0.70) HIF1AHSD17B10NR3C1PGRCYP3A4
SCHEMBL719929 0.90 HIF1A (0.70) HIF1AHSD17B10NR3C1PGRCYP3A4
SCHEMBL28074680 0.90 HIF1A (0.70) HIF1AHSD17B10NR3C1PGRCYP3A4
SCHEMBL11406889 0.90 HIF1A (0.70) HIF1AHSD17B10NR3C1PGRCYP3A4
SCHEMBL28344376 0.90 HIF1A (0.70) HIF1AHSD17B10NR3C1PGRCYP3A4
SCHEMBL4622168 0.90 HIF1A (0.70) HIF1AHSD17B10NR3C1PGRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230310634-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF IMMUNEXT INC (US) 2023-10-05 — — US claimed
EP-4136118-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF Immunext, Inc. (US) 2023-02-22 — — EP claimed
WO-2021216913-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF IMMUNEXT, INC. (US) 2021-10-28 — — WO claimed
WO-2008049401-A2 NAIL VARNISH FOR COSMETIC AND MEDICAL APPLICATIONS SUSILO RUDY (DE) 2008-05-02 — — WO claimed
EP-4314004-A1 CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS Eli Lilly and Company (US) 2024-02-07 — — EP disclosed
EP-4314005-A1 GLUCOCORTICOID RECEPTOR AGONISTS Eli Lilly and Company (US) 2024-02-07 — — EP disclosed
US-20230382916-A1 HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2023-11-30 — — US disclosed
EP-4271387-A1 NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCS CONTAINING AND USE THEREOF Immunext, Inc. (US) 2023-11-08 — — EP disclosed
US-20230310634-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF IMMUNEXT INC (US) 2023-10-05 — — US disclosed
EP-4214206-A1 HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF Hutchison Medipharma Limited (CN) 2023-07-26 — — EP disclosed
US-11655254-B2 Substituted piperazines as BTK inhibitors HUTCHISON MEDIPHARMA LIMITED (CN) 2023-05-23 — — US disclosed
EP-4136118-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF Immunext, Inc. (US) 2023-02-22 — — EP disclosed
US-5322695-A Controlled release, wound healing topical medicant for human skin HERCON LABORATORIES CORPORATION (US) 1994-06-21 — — US disclosed
US-5310559-A Device for controlled release and delivery to mammalian tissue of pharmacologically active agents incorporating a rate controlling member which comprises an alkylene-alkyl acrylate copolymer HERCON LABORATORIES CORPORATION (US) 1994-05-10 — — US disclosed
EP-0251425-B1 ARTICLE FOR ADMINISTRATION OF PHARMACOLOGICALLY-ACTIVE SUBSTANCES HERCON LABORATORIES CORPORATION (US) 1993-06-16 — — EP disclosed
US-RE34089-E Solid plastisol layer of polyvinyl chloride, a plasticizer and a drug which is applied to tissues wherein drug is absorbed into the vascular system; controlled release of drugs HERCON LABORATORIES CORPORATION (US) 1992-10-06 — — US disclosed
US-4767808-A POLYVINYL CHLORIDE WITH N-DODECYLCAPROLACTAM OR N,N-DIETHYLTOLUAMIDE PLASTICIZER HERCON LABORATORIES CORPORATION (US) 1988-08-30 — — US disclosed
US-4758434-A Article useful for administration of pharmacologically-active substances transdermally, orally, or by means of implant HERCON LABORATORIES CORPORATION (US) 1988-07-19 — — US disclosed
US-4528271-A Process for the intensification of microbiological conversions of steroids using cyclodextrin additives RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 1985-07-09 — — US disclosed
US-3899580-A Anti-inflammatory topical gel MERCK & CO INC 1975-08-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382916-A1 HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF CYP3A43, CYP3A5, CYP3A7 HIF1A 1558/4885HSD17B10 182/4885NR3C1 1829/4885
US-20230310634-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF CD47, CLTA, FCGR2A HIF1A 2042/4885HSD17B10 2405/4885NR3C1 104/4885
US-11655254-B2 Substituted piperazines as BTK inhibitors BTK, SYK, LYN HIF1A 4094/4885HSD17B10 4227/4885NR3C1 2076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.